ゴーシェ病薬の世界市場2020-2026:酵素、グルコシルセラミド合成酵素阻害剤、骨粗鬆症治療薬代替品

QYResearchが発行した調査報告書(QYR20AP00844)
◆英語タイトル:Global Gaucher Disease Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP00844
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:116
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、ゴーシェ病薬の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、ゴーシェ病薬のグローバル市場動向、メーカー別競争状況、種類別市場規模(酵素、グルコシルセラミド合成酵素阻害剤、骨粗鬆症治療薬代替品)、用途別市場規模(I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・ゴーシェ病薬の種類別市場2015-2026:酵素、グルコシルセラミド合成酵素阻害剤、骨粗鬆症治療薬代替品
・ゴーシェ病薬の用途別市場2015-2026:I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病
・ゴーシェ病薬の北米市場分析
・ゴーシェ病薬のアジア市場分析
・ゴーシェ病薬の中南米市場分析
・ゴーシェ病薬の中東・アフリカ市場分析
・関連企業情報:Dong-A-Socio Holdings、Genzyme Corporation、ExSAR Corporation、Neuraltus Pharmaceuticals、Amicus Therapeutics、JCR Pharmaceuticals、Lixte Biotechnology Holdings、Protalix BioTherapeutics、Greenovation Biotech
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

In 2019, the global Gaucher Disease Drugs market size was US$ 1321 million and is forecast to US$ 1380.5 million in 2026, growing at a CAGR of 0.6% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Gaucher Disease Drugs.The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Gaucher Disease Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Gaucher Disease Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Gaucher Disease Drugs market. Readers of the report can become informed about current and future trends of the global Gaucher Disease Drugs market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Gaucher Disease Drugs markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Gaucher Disease Drugs market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Gaucher Disease Drugs market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Gaucher Disease Drugs market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Gaucher Disease Drugs market is segmented into
Replace Enzymes
Glucosylceramide Synthase Inhibitors
Osteoporosis Drugs

Market Segment by Application, the Gaucher Disease Drugs market is segmented into
Type I Gaucher Disease
Type II Gaucher Disease
Type III Gaucher Disease

This report includes the following manufacturers; we can also add the other companies as you want.
Dong-A-Socio Holdings
Genzyme Corporation
ExSAR Corporation
Neuraltus Pharmaceuticals
Amicus Therapeutics
JCR Pharmaceuticals
Lixte Biotechnology Holdings
Protalix BioTherapeutics
Greenovation Biotech

The study objectives are:
To analyze and research the global Gaucher Disease Drugs status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Gaucher Disease Drugs manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Gaucher Disease Drugs are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Gaucher Disease Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Gaucher Disease Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Replace Enzymes
1.3.3 Glucosylceramide Synthase Inhibitors
1.3.4 Osteoporosis Drugs
1.4 Market Segment by Application
1.4.1 Global Gaucher Disease Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Type I Gaucher Disease
1.4.3 Type II Gaucher Disease
1.4.4 Type III Gaucher Disease
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Gaucher Disease Drugs Revenue (2015-2026)
2.1.1 Global Gaucher Disease Drugs Revenue (2015-2026)
2.1.2 Global Gaucher Disease Drugs Sales (2015-2026)
2.2 Gaucher Disease Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Gaucher Disease Drugs Sales by Regions (2015-2020)
2.2.2 Global Gaucher Disease Drugs Revenue by Regions (2015-2020)
2.3 Global Top Gaucher Disease Drugs Regions (Countries) Ranking by Market Size
2.4 Gaucher Disease Drugs Industry Trends
2.4.1 Gaucher Disease Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Gaucher Disease Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Gaucher Disease Drugs Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Gaucher Disease Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Gaucher Disease Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Gaucher Disease Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Gaucher Disease Drugs Sales in 2019
3.2 Global Top Manufacturers Gaucher Disease Drugs by Revenue
3.2.1 Global Gaucher Disease Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Gaucher Disease Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Gaucher Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gaucher Disease Drugs as of 2019)
3.4 Global Gaucher Disease Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Gaucher Disease Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Gaucher Disease Drugs Market
3.7 Key Manufacturers Gaucher Disease Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Gaucher Disease Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Gaucher Disease Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Gaucher Disease Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Gaucher Disease Drugs Price by Type (2015-2020)
4.1 Global Gaucher Disease Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Gaucher Disease Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Gaucher Disease Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Gaucher Disease Drugs Price Forecast by Type (2021-2026)

5 Global Gaucher Disease Drugs Market Size by Application
5.1 Global Gaucher Disease Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Gaucher Disease Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Gaucher Disease Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Gaucher Disease Drugs Price by Application (2015-2020)
5.2 Global Gaucher Disease Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Gaucher Disease Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Gaucher Disease Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Gaucher Disease Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Gaucher Disease Drugs Breakdown Data by Company
6.2 North America Gaucher Disease Drugs Breakdown Data by Type
6.3 North America Gaucher Disease Drugs Breakdown Data by Application
6.4 North America Gaucher Disease Drugs Breakdown Data by Countries
6.4.1 North America Gaucher Disease Drugs Sales by Countries
6.4.2 North America Gaucher Disease Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Gaucher Disease Drugs Breakdown Data by Company
7.2 Europe Gaucher Disease Drugs Breakdown Data by Type
7.3 Europe Gaucher Disease Drugs Breakdown Data by Application
7.4 Europe Gaucher Disease Drugs Breakdown Data by Countries
7.4.1 Europe Gaucher Disease Drugs Sales by Countries
7.4.2 Europe Gaucher Disease Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Gaucher Disease Drugs Breakdown Data by Company
8.2 Asia Pacific Gaucher Disease Drugs Breakdown Data by Type
8.3 Asia Pacific Gaucher Disease Drugs Breakdown Data by Application
8.4 Asia Pacific Gaucher Disease Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Gaucher Disease Drugs Sales by Regions
8.4.2 Asia Pacific Gaucher Disease Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Gaucher Disease Drugs Breakdown Data by Company
9.2 Latin America Gaucher Disease Drugs Breakdown Data by Type
9.3 Latin America Gaucher Disease Drugs Breakdown Data by Application
9.4 Latin America Gaucher Disease Drugs Breakdown Data by Countries
9.4.1 Latin America Gaucher Disease Drugs Sales by Countries
9.4.2 Latin America Gaucher Disease Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Gaucher Disease Drugs Breakdown Data by Type
10.2 Middle East and Africa Gaucher Disease Drugs Breakdown Data by Application
10.3 Middle East and Africa Gaucher Disease Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Gaucher Disease Drugs Sales by Countries
10.3.2 Middle East and Africa Gaucher Disease Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Dong-A-Socio Holdings
11.1.1 Dong-A-Socio Holdings Corporation Information
11.1.2 Dong-A-Socio Holdings Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Dong-A-Socio Holdings Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Dong-A-Socio Holdings Gaucher Disease Drugs Products and Services
11.1.5 Dong-A-Socio Holdings SWOT Analysis
11.1.6 Dong-A-Socio Holdings Recent Developments
11.2 Genzyme Corporation
11.2.1 Genzyme Corporation Corporation Information
11.2.2 Genzyme Corporation Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Genzyme Corporation Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Genzyme Corporation Gaucher Disease Drugs Products and Services
11.2.5 Genzyme Corporation SWOT Analysis
11.2.6 Genzyme Corporation Recent Developments
11.3 ExSAR Corporation
11.3.1 ExSAR Corporation Corporation Information
11.3.2 ExSAR Corporation Business Overview and Total Revenue (2019 VS 2018)
11.3.3 ExSAR Corporation Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 ExSAR Corporation Gaucher Disease Drugs Products and Services
11.3.5 ExSAR Corporation SWOT Analysis
11.3.6 ExSAR Corporation Recent Developments
11.4 Neuraltus Pharmaceuticals
11.4.1 Neuraltus Pharmaceuticals Corporation Information
11.4.2 Neuraltus Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Neuraltus Pharmaceuticals Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Neuraltus Pharmaceuticals Gaucher Disease Drugs Products and Services
11.4.5 Neuraltus Pharmaceuticals SWOT Analysis
11.4.6 Neuraltus Pharmaceuticals Recent Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Corporation Information
11.5.2 Amicus Therapeutics Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Amicus Therapeutics Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Amicus Therapeutics Gaucher Disease Drugs Products and Services
11.5.5 Amicus Therapeutics SWOT Analysis
11.5.6 Amicus Therapeutics Recent Developments
11.6 JCR Pharmaceuticals
11.6.1 JCR Pharmaceuticals Corporation Information
11.6.2 JCR Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.6.3 JCR Pharmaceuticals Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 JCR Pharmaceuticals Gaucher Disease Drugs Products and Services
11.6.5 JCR Pharmaceuticals SWOT Analysis
11.6.6 JCR Pharmaceuticals Recent Developments
11.7 Lixte Biotechnology Holdings
11.7.1 Lixte Biotechnology Holdings Corporation Information
11.7.2 Lixte Biotechnology Holdings Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Lixte Biotechnology Holdings Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Lixte Biotechnology Holdings Gaucher Disease Drugs Products and Services
11.7.5 Lixte Biotechnology Holdings SWOT Analysis
11.7.6 Lixte Biotechnology Holdings Recent Developments
11.8 Protalix BioTherapeutics
11.8.1 Protalix BioTherapeutics Corporation Information
11.8.2 Protalix BioTherapeutics Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Protalix BioTherapeutics Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Protalix BioTherapeutics Gaucher Disease Drugs Products and Services
11.8.5 Protalix BioTherapeutics SWOT Analysis
11.8.6 Protalix BioTherapeutics Recent Developments
11.9 Greenovation Biotech
11.9.1 Greenovation Biotech Corporation Information
11.9.2 Greenovation Biotech Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Greenovation Biotech Gaucher Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Greenovation Biotech Gaucher Disease Drugs Products and Services
11.9.5 Greenovation Biotech SWOT Analysis
11.9.6 Greenovation Biotech Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Gaucher Disease Drugs Sales Channels
12.2.2 Gaucher Disease Drugs Distributors
12.3 Gaucher Disease Drugs Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Gaucher Disease Drugs Sales Forecast (2021-2026)
13.1.1 Global Gaucher Disease Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Gaucher Disease Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Gaucher Disease Drugs Sales Forecast (2021-2026)
13.2.2 North America Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.2.3 North America Gaucher Disease Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Gaucher Disease Drugs Sales Forecast (2021-2026)
13.3.2 Europe Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Gaucher Disease Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Gaucher Disease Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Gaucher Disease Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Gaucher Disease Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Gaucher Disease Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Gaucher Disease Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Gaucher Disease Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Gaucher Disease Drugs Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Dong-A-Socio Holdings、Genzyme Corporation、ExSAR Corporation、Neuraltus Pharmaceuticals、Amicus Therapeutics、JCR Pharmaceuticals、Lixte Biotechnology Holdings、Protalix BioTherapeutics、Greenovation Biotech

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ ゴーシェ病薬の世界市場2020-2026:酵素、グルコシルセラミド合成酵素阻害剤、骨粗鬆症治療薬代替品(Global Gaucher Disease Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。